Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to $137.0 million.

  • Kyntra Bio's Liabilities and Shareholders Equity fell 4818.34% to $137.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $694.8 million, marking a year-over-year decrease of 4841.9%. This contributed to the annual value of $214.5 million for FY2024, which is 4934.82% down from last year.
  • Kyntra Bio's Liabilities and Shareholders Equity amounted to $137.0 million in Q3 2025, which was down 4818.34% from $178.1 million recorded in Q2 2025.
  • In the past 5 years, Kyntra Bio's Liabilities and Shareholders Equity ranged from a high of $850.5 million in Q3 2021 and a low of $137.0 million during Q3 2025
  • In the last 5 years, Kyntra Bio's Liabilities and Shareholders Equity had a median value of $515.1 million in 2023 and averaged $496.2 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 474.1% in 2021, then crashed by 5484.36% in 2025.
  • Quarter analysis of 5 years shows Kyntra Bio's Liabilities and Shareholders Equity stood at $773.8 million in 2021, then fell by 21.16% to $610.1 million in 2022, then plummeted by 30.58% to $423.5 million in 2023, then tumbled by 49.35% to $214.5 million in 2024, then plummeted by 36.13% to $137.0 million in 2025.
  • Its Liabilities and Shareholders Equity was $137.0 million in Q3 2025, compared to $178.1 million in Q2 2025 and $165.2 million in Q1 2025.